|
Summaries of Product Characteristics (SPC) for Human medicinal products
The summaries of product characteristics (SPC) contain the information relevant to the use of the medicinal products and of importance to health care professionals. The SPCs are published in Finnish; the use of Finnish key words in the search fields is therefore recommended.
Some of the medicinal products contain a condition relevant to the prescribing of the product and not always found in the SPC. The conditions for prescribing and the products covered by this condition are found in the FimeaWeb search.
The SPCs processed as part of the EU centralised marketing authorisation procedure are published by the European Medicines Agency, EMA. Fimea's service contains links to the documents on medicinal products (EPAR PI) on the EMA website. Drugs belonging to the centralised authorisation procedure can be searched in Fimea's service by using an alphabetical list or by entering the product name or ATC code.
The material being published is not necessarily complete or up-to-date due to the technical quality of files submitted to the Finnish Medicines Agency Fimea or earlier to the National Agency for Medicines and the delays in delivery. For this reason, Fimea cannot guarantee that the document on the Internet fully complies with the summary of product characteristics and package leaflet officially approved by a desicion for a marketing authorisation. Only the hard copies of the SPCs and the PLs, which are in accordance with the marketing authorisation, are conclusive.
Summaries of Product Characteristics 1 - 30 of 208 |
|
|
Package leaflet | Status for supply | Name of the medicinal product |
|
|
European Medicines Agency's website: Naglazyme - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Naldix 50 mg tabletti, kalvopäällysteinen SPC 2023-02-28
|
PL
|
Resepti
|
Nalgesin 220 mg tabletti, kalvopäällysteinen SPC 2023-04-13
|
PL
|
Resepti
|
Naloxon B. Braun 0.4 mg-ml injektio-infuusioneste, liuos SPC 2019-09-26
|
PL
|
Resepti
|
Naloxone Accord 0,4 mg-ml injektio-infuusioneste, liuos, esitäytetty ruisku SPC 2023-02-01.docx
|
PL
|
Resepti
|
Naltrexon Accord 50 mg tabletti, kalvopäällysteinen SPC 2024-06-14
|
PL
|
Resepti
|
Naltrexon Vitaflo 50 mg tabletti, kalvopäällysteinen SPC 2022-03-18
|
PL
|
Resepti
|
Naltrexone Poa Pharma 50 mg tabletti, kalvopäällysteinen SPC 2023-02-28
|
|
|
European Medicines Agency's website: Namuscla - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Nanogam 100 mg-ml infuusioneste, liuos SPC 2022-11-17
|
PL
|
Resepti
|
Nanogam 50 mg-ml infuusioneste, liuos SPC 2021-12-17
|
PL
|
Resepti
|
Naprometin 500 mg tabletti SPC 2023-03-23
|
PL
|
Resepti
|
Napromex 500 mg tabletti, kalvopäällysteinen SPC 2024-07-05
![Uusi](/indox/nam/i/lamppu3.png)
|
PL
|
Resepti
|
Naproxen Krka 550 mg tabletti, kalvopäällysteinen SPC 2022-09-22
|
PL
|
Resepti
|
Naproxen Orion 250 mg, 500 mg tabletti SPC 2022-09-14
|
PL
|
Resepti
|
Naramig 2.5 mg tabletti, kalvopäällysteinen SPC 2023-09-22
|
PL
|
Resepti
|
Naratriptan Orifarm 2.5 mg tabletti SPC 2021-12-02
|
PL
|
Resepti/itsehoito
|
Nasacort 55 mikrog-annos nenäsumute, suspensio SPC 2023-07-15
|
PL
|
Itsehoito
|
Nasment 1 mg-ml nenäsumute, liuos SPC 2021-05-13
|
PL
|
Itsehoito
|
Naso-Ratiopharm 0.5 mg-ml, 1 mg-ml nenäsumute, liuos SPC 2021-02-08
|
PL
|
Resepti/itsehoito
|
Nasofan 50 mikrog-annos nenäsumute, suspensio SPC 2022-09-29
|
PL
|
Itsehoito
|
Nasolin 0.5 mg-ml, 1 mg-ml nenäsumute, liuos SPC 2024-03-05
|
PL
|
Itsehoito
|
Nasolin 0.5 mg-ml, 1 mg-ml nenäsumute, liuos SPC 2024-03-05
|
PL
|
Resepti
|
Nasonex 50 mikrog-annos nenäsumute, suspensio SPC 2021-04-27
|
|
|
European Medicines Agency's website: Natpar - EMA: EPAR PI
Finnish Swedish
|
PL
|
Itsehoito
|
Natr. Chlorid. 9 mg-ml nenätipat, liuos SPC 2021-06-07
|
PL
|
Resepti
|
Natrilix 2.5 mg tabletti, kalvopäällysteinen SPC 2021-12-21
|
PL
|
Resepti
|
Natrilix Retard 1.5 mg depottabletti SPC 2021-11-24
|
PL
|
Resepti
|
Natriumbicarbonate Braun 75 mg-ml infuusioneste SPC 2020-01-09
|
PL
|
Resepti
|
Natriumfluoridi Morningside 5 mg-g hammastahna SPC 2022-08-04
|
|
| |